This is a snippet of the transcript, sign up to read more.
In hindsight, it's obviously 20/20, but it was so close to passing. In the armor business, you need 80 front carrier plates, 80 armor plates, and they shoot a bullet at each one. If one out of 80 has the bullet poke through on the other side, it's a failure, and you lose the whole thing. I don't know how it all ended. I don't really know the end game of the armor situation. We just knew that Avon was tired of investing money to try to make it work. We tried two or three times to make it happen.
This is a snippet of the transcript, sign up to read more.
I don't know the financial decision behind it. You might think, "Let's just sell it," but writing it off or winding it down was more economically feasible for some reason. I never got really involved with the armor. My hunch is that 3M packaged the armor in the deal just to unload it. They might have known, but that's just speculation on my part.
This is a snippet of the transcript, sign up to read more.
That's a complex question. The ownership has changed over the years. Avon can use some designs for other products, which is why masks like the C50 and M50 look similar. The C50 is commercial, while the M50 is military, with subtle differences that make it an ITAR-controlled product. These differences could involve valve functions or filter capabilities, and the government tightly controls these specs.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research